LXRX

Over the past six months, Lexicon Pharmaceuticals participated in investor conferences in May and September 2026, and presented data at the American Diabetes Association (ADA) 2026 Scientific Sessions on June 3, 2026. On July 27, 2026, the company completed enrollment of its pivotal Phase 3 SONATA-HCM study of sotagliflozin, with top-line results anticipated in Q1 2027. Lexicon reported its Second Quarter 2026 financial results on August 6, 2026, and earned a $10 million milestone payment from Novo Nordisk for LX9851 on August 24, 2026. On August 31, 2026, new post hoc SOLOIST-WHF analysis demonstrated consistent sotagliflozin results across baseline blood pressure levels in patients with recent worsening heart failure. In September 2026, the consensus price target for Lexicon Pharmaceuticals was increased by 17.91% to $4.64 per share. The stock experienced a 1-month change of -18.8% from September 2, 2026, to October 2, 2026, and on October 8, 2026, it started trading at $1.73, a drop of 1.42% compared to the previous day's closing price.